1. Home
  2. IDE vs CUE Comparison

IDE vs CUE Comparison

Compare IDE & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

IDE

Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

HOLD

Current Price

$13.22

Market Cap

200.8M

Sector

Finance

ML Signal

HOLD

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

HOLD

Current Price

$28.16

Market Cap

233.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDE
CUE
Founded
2010
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
200.8M
233.5M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
IDE
CUE
Price
$13.22
$28.16
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$120.00
AVG Volume (30 Days)
37.9K
195.4K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
8.83%
N/A
EPS Growth
N/A
61.11
EPS
N/A
N/A
Revenue
N/A
$27,466,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
195.75
52 Week Low
$11.36
$0.17
52 Week High
$14.30
$45.50

Technical Indicators

Market Signals
Indicator
IDE
CUE
Relative Strength Index (RSI) 46.71 49.86
Support Level $13.05 $24.70
Resistance Level $13.46 $33.95
Average True Range (ATR) 0.13 3.81
MACD 0.02 0.01
Stochastic Oscillator 53.85 43.59

Price Performance

Historical Comparison
IDE
CUE

About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

Share on Social Networks: